Series A investiment for Phase I/II trials

EVOMEDIS is a pre-clinical stage R&D biotech company founded 2020 in Graz, Austria that aims to revolutionize wound care by developing the first off-the-shelf, freeze-dried, living healing system, using human allogenic keratinocytes for the treatment of both acute and chronic wounds as well as repair of other epithelial lesions. Building on years of R&D (since 2015 > €5.0M invested), the Company has developed a patented technology platform with the lead project EVOCellic, a bioactive cell depot (BCD), which after application creates a “healing enclave” on the wounds. This first-in-class, freeze-dried and easy to store formulation (+4°C > 12 months) will be developed creating a cost-efficient, scalable, and globally accessible therapy that accelerates healing, reduces complications, and shifts the paradigm from wound management to wound healing especially saving lives of children, elderly people and trauma patients. EVOCellic addresses approximately 11 million hospitalized burn patients and 50 million chronic wound patients worldwide within the advanced wound care market projected at $16 billion in 2025. The BCD platform further expands into acute lung injury and fibrosis ($4.5 billion market, EVOLung), corneal lesions ($0.9 billion market, EVOEye), and hair loss ($7.9 billion market, EVOHair).

EVOMEDIS is raising investments for a Series A round to complete two Phase I/II trials in burn and diabetic foot ulcer patients, with data expected in 2029. These data and solid pre-clinical data packages for the other BCD development candidates will open multiple revenue streams: direct sales to hospitals & burn centers, strategic licensing deals and milestone-based payments.

MANAGEMENT TEAM

Dr. Martin Funk brings 30 years of experience in biotechnology R&D, spanning early discovery to market entry across small molecules, biologics, and cell therapies. Until 2012, he served as Head of Portfolio & Project Management at MediGene AG and afterwards led and founded several biotech companies.

Dr. Ives Bernardelli de Mattos holds a PhD in Tissue Engineering and has over 10 years of experience in wound healing research. He has authored numerous scientific publications and maintains a strong international network of key opinion leaders in regenerative medicine.

Dr. Alexandru Tuca is a board-certified plastic surgeon and regenerative medicine researcher focused on translating innovative science into clinical practice. He drives the company’s strategy of developing new therapies in close collaboration with medical end-users to ensure real-world impact.

IPs

WO2017032614A1 Granted in EU, US, CA, CN, IN, BR, CL, CL, MX, PE; WO2024104577A1 Published 2024-05-23; EP4615576A1 published 2025-09-17; Additional patents covering the core technology submitted or planned; Future IPs will cover different therapeutic approaches arising from the technology platform; EU/3/22/2637 ODD - orphan designation for treatment of partial deep dermal and full thickness burns.